DATE: April 1, 2020
TO: UCH Medical Staff, House staff, Patient Care Centers, and Outpatient Clinics
FROM: Kathleen G. Beavis, MD, Professor of Pathology and Medical Director of Microbiology and Immunology Laboratory
Scott M. Matushek, MS, M(ASCP), Laboratory Manager, Clinical Microbiology and Immunology Laboratory
RE: Implementation April 1, 2020: Cepheid Rapid Xpert Xpress SARS-CoV-2 Test and NASAL collection for COVID-19 (SARS-CoV-2) patient testing

The UCM Clinical Microbiology and Immunology Laboratories currently performs testing for the agent of COVID-19 (SARS-CoV-2) using the Roche cobas® SARS-CoV-2 RT-PCR high throughput assay. This testing is batched and performed several times throughout the day, with results available in <24 hours.

Additional COVID-19 (SARS-CoV-2) Assay:

The Xpert Xpress SARS-CoV-2 test is a rapid PCR assay intended for the qualitative detection of nucleic acid from the SARS-CoV-2. This test will be performed 24/7, requires 45 minutes of analytic time, and results should be available within 3 hours of receipt in the Microbiology Lab, depending on the volume of requests. The Xpert Xpress SARS-CoV-2 test and the cobas® SARS-CoV-2 RT-PCR have equivalent performance.

Specimen and transport requirements:

Testing is routinely performed on flocked nasopharyngeal swabs collected in Universal Viral Transport Medium. This is the same collection currently used for Respiratory Viral Panel testing (order code RVP) and Influenza A/B and RSV PCR (order code IRP).

- If both COVID-19 and RVP or IRP testing are ordered, a single sample can be collected; make certain to label transport tube with both orders.

As an additional option, testing for COVID-19 only can be performed on both Roche and Cepheid platforms using nasal swabs collected in eSwab liquid Amies transport medium (Oracle 250563). No additional testing can be added to this order.

**Flocked Nasal Swab Specimen Collection**
Kit consists of flocked swab and ESwab Collection & Transport media.
1. Insert the flocked swab into the patient’s nostril until a slight resistance is met.
2. Rotate the flocked swab 2-3 times and hold the swab in place for 5-10 seconds to ensure maximum absorbency.
3. Repeat in the second nostril with the same swab.
4. Place the swab in the viral transport media and break the shaft at the designated breakpoint.
5. Tightly close the lid.

**Test ordering information:**
This test is available for predetermined patient populations through the AgileMD pathway.

If you have any questions, please contact Scott Matushek, Laboratory Manager, in the Clinical Microbiology and Immunology Laboratories at 773-702-4116 or Kathleen G. Beavis, MD.
FACT SHEET FOR PATIENTS

Xpert® Xpress SARS-CoV-2 – Cepheid

March 20, 2020

Coronavirus Disease 2019 (COVID-19)

You are being given this Fact Sheet because your sample(s) was tested for the Coronavirus Disease 2019 (COVID-19) using the Xpert Xpress SARS-CoV-2 test.

This Fact Sheet contains information to help you understand the risks and benefits of using this test for the diagnosis of COVID-19. After reading this Fact Sheet, if you have questions or would like to discuss the information provided, please talk to your healthcare provider.

For the most up to date information on COVID-19 please visit the CDC Coronavirus Disease 2019 (COVID-19) webpage:

https://www.cdc.gov/COVID19

What is COVID-19?
COVID-19 is caused by the SARS-CoV-2 virus. The virus, which can cause mild to severe respiratory illness, was first identified in Wuhan, China, and has now spread globally, including the United States. There is limited information available to characterize the spectrum of clinical illness associated with COVID-19 but it likely spreads to others when a person shows signs or symptoms of being sick (e.g., fever, coughing, difficulty breathing, etc.).

What is the Xpert Xpress SARS-CoV-2 test?
The test is designed to detect the virus that causes COVID-19 in respiratory specimens, for example nasal or oral swabs.

Why was my sample tested?
You were tested because your healthcare provider believes you may have been exposed to the virus that causes COVID-19 based on your signs and symptoms (e.g., fever, cough, difficulty breathing), and/or because:

• You live in or have recently traveled to a place where transmission of COVID-19 is known to occur, and/or
• You have been in close contact with an individual suspected of or confirmed to have COVID-19.

Testing of the samples will help find out if you may have COVID-19.

What are the known and potential risks and benefits of the test?
Potential risks include:

• Possible discomfort or other complications that can happen during sample collection.
• Possible incorrect test result (see below for more information).

Potential benefits include:

• The results, along with other information, can help your healthcare provider make informed recommendations about your care.
• The results of this test may help limit the spread of COVID-19 to your family and others in your community.

What does it mean if I have a positive test result?
If you have a positive test result, it is very likely that you have COVID-19. Therefore, it is also likely that you may be placed in isolation to avoid spreading the virus to others. There is a very small chance that this test can

Where can I go for updates and more information? The most up-to-date information on COVID-19 is available at the CDC General webpage: https://www.cdc.gov/COVID19. In addition, please also contact your healthcare provider with any questions/concerns.
FACT SHEET FOR PATIENTS

Xpert® Xpress SARS-CoV-2—Cepheid

March 20, 2020

Coronavirus Disease 2019 (COVID-19)

give a positive result that is wrong (a false positive result). Your healthcare provider will work with you to determine how best to care for you based on the test results along with medical history, and your symptoms.

What does it mean if I have a negative test result?
A negative test result means that the virus that causes COVID-19 was not found in your sample. For COVID-19, a negative test result for a sample collected while a person has symptoms usually means that COVID-19 did not cause your recent illness.

However, it is possible for this test to give a negative result that is incorrect (false negative) in some people with COVID-19. This means that you could possibly still have COVID-19 even though the test is negative. If this is the case, your healthcare provider will consider the test result together with all other aspects of your medical history (such as symptoms, possible exposures, and geographical location of places you have recently traveled) in deciding how to care for you.

It is important that you work with your healthcare provider to help you understand the next steps you should take.

Is this test FDA-approved or cleared?
No. This test is not yet approved or cleared by the United States FDA. When there are no FDA-approved or cleared tests available, and other criteria are met, FDA can make tests available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA for this test is supported by the Secretary of Health and Human Service’s (HHS’s) declaration that circumstances exist to justify the emergency use of in vitro diagnostics for the detection and/or diagnosis of the virus that causes COVID-19. This EUA will remain in effect (meaning this test can be used) for the duration of the COVID-19 declaration.

Where can I go for updates and more information? The most up-to-date information on COVID-19 is available at the CDC General webpage: https://www.cdc.gov/COVID19. In addition, please also contact your healthcare provider with any questions/concerns.
This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the Xpert Xpress SARS-CoV-2 test.

The Xpert Xpress SARS-CoV-2 test is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider.

All patients whose specimens are tested with this assay will receive the Fact Sheet for Patients: Xpert Xpress SARS-CoV-2 test.

What are the symptoms of COVID-19?
Many patients with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing). However, limited information is currently available to characterize the full spectrum of clinical illness associated with COVID-19. Based on what is known about the virus that causes COVID-19, signs and symptoms may appear any time from 2 to 14 days after exposure to the virus. Based on preliminary data, the median incubation period is approximately 5 days, but may range 2-14 days.

Public health officials have identified cases of COVID-19 infection throughout the world, including the United States, which may pose risks for public health. Please check the CDC webpage for the most up to date information.

What do I need to know about COVID-19 testing?
Current information on COVID-19 for healthcare providers is available at CDC's webpage, Information for Healthcare Professionals (see links provided in "Where can I go for updates and more information" section).

- The Xpert Xpress SARS-CoV-2 test should be ordered for the detection of COVID-19 in individuals suspected of COVID-19 by their healthcare provider.
- The Xpert Xpress SARS-CoV-2 test can be used to test nasopharyngeal swabs and nasal wash/aspirate specimens in using the GeneXpert Dx and GeneXpert Infinity systems in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate or high complexity tests in accordance with the Xpert Xpress SARS-CoV-2 Instructions for Use - For Use with GeneXpert Dx or GeneXpert Infinity systems.
- The Xpert Xpress SARS-CoV-2 test can be used to test nasopharyngeal swabs using the GeneXpert Xpress System (Tablet and Hub Configurations) in patient care settings outside of the clinical laboratory environment in accordance with the point of care Xpert Xpress SARS-CoV-2 Instructions for Use - For Use with GeneXpert Xpress System, Quick Reference Instructions for Xpert Xpress SARS-CoV-2 and GeneXpert Xpress System (Hub configuration), and Quick Reference Instructions for Xpert Xpress SARS-CoV-2 and GeneXpert Xpress System (Tablet configuration).

Specimens should be collected with appropriate infection control precautions. Current guidance for COVID-19 infection control precautions are available at the CDC’s website (see links provided in “Where can I go for updates and more information” section).

Use appropriate personal protective equipment when collecting and handling specimens from individuals suspected of having COVID-19 as outlined in the CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19). For additional information, refer to CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PIUs) for Coronavirus Disease 2019 (COVID-19) (see links provided in “Where can I go for updates and more information” section).

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088.
What does it mean if the specimen tests positive for the virus that causes COVID-19?
A positive test result for COVID-19 indicates that RNA from SARS-CoV-2 was detected, and the patient is infected with the virus and presumed to be contagious. Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making a final diagnosis and patient management decisions. Patient management should follow current CDC guidelines.

The Xpert Xpress SARS-CoV-2 test has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks to patients could include the following: a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other potentially COVID-19 patients, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or therapy, or other unintended adverse effects.

All laboratories and healthcare providers in patient care settings using this test must follow the standard testing and reporting guidelines according to their appropriate public health authorities.

What does it mean if the specimen tests negative for the virus that causes COVID-19?
A negative test result for this test means that SARS-CoV-2 RNA was not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions. A negative result does not exclude the possibility of COVID-19.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation indicate that COVID-19 is likely, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. If COVID-19 is still suspected based on exposure history together with other clinical findings, re-testing should be considered by healthcare providers in consultation with public health authorities.

Risks to a patient of a false negative include: delayed or lack of supportive treatment, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events.

What is an EUA?
The United States (U.S.) FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Services (HHS)'s declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19.

An IVD made available under an EUA has not undergone the same type of review as an FDA-approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective in the detection of the virus that causes COVID-19.

The EUA for this test is in effect for the duration of the COVID-19 declaration justifying emergency use of IVDs, unless terminated or revoked (after which the test may no longer be used).

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088
Where can I go for updates and more information?

**CDC webpages:**
- General: https://www.cdc.gov/COVID19

**FDA webpages:**
- General: www.fda.gov/novelcoronavirus
- EUAs: (Includes links to patient fact sheet and manufacturer’s instructions) https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations

**Cepheid:**
- 904 Caribbean Drive
- Sunnyvale, CA 94089 USA
- Phone: +1 408 541 4191
- Email: TechSupport@cepheid.com
- Technical Services Phone: +1 888 838 3222
- International Phone: +33 563 825 319
- Website: http://www.cepheid.com

---

*Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088*